Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
PERCHERON THERAPEUTICS LIMITED (PER)ASX AI Signals has generated 8 signals for PER during the last 90 days, indicating strong trading activity and ongoing AI monitoring
Latest PER Signals | |
| 23/06/2026 | SELL |
| 22/06/2026 | BUY |
| 21/06/2026 | BUY |
PER Share Price | |
| Current Price | $0.004 |
| 52 Week High | $0.011 |
| 52 Week Low: | $0.003 |
| Trading at (% of 52 Week High) | 36.36% |
Percheron Therapeutics Limited (ASX: PER) is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that target inflammation and fibrosis. The company’s key programs include treatments for autoimmune and inflammatory diseases using its proprietary technology. Percheron aims to improve patient outcomes through innovative drug development.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
The SELL recommendation for PERCHERON THERAPEUTICS LIMITED is supported by the extremely low stock price indicating potential distress or lack of market confidence, combined with typical risks associated with small-cap biotech firms such as high volatility and uncertain clinical outcomes.
The S&P/ASX Small Ordinaries Index (ASX: XSO) finished at 3,505 points, down 6.4 points or 0.18% in the latest session, but remains up 48 points or 1.39% over the past five trading days, reflecting continued resilience across the small-cap sector despite broader market volatility.
Gold explorers an Percheron opens entitlement offer to eligible shareholders Proactive uses images sourced from Shutterstock
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has opened its non-renounceable pro rata entitlement offer to eligible shareholders, making the prospectus and personalised entitlement and acceLatest PERCHERON THERAPEUTICS LIMITED(PER) News
Small cap Watch: Biotech, gold explorers and consumer brands deliver key updates
Percheron opens entitlement offer to eligible shareholders
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial